Perseid Therapeutics LLC

Cytomx Therapeutics, Inc.

Maxygen, Inc.

Dice Molecules Sv, LLC

Astellas Pharma Gmbh

Madan M Paidhungat

Steven Henry Bass

Juha Punnonen

Erik E Karrer

Margaret Neighbors

Phillip A Patten

Sridhar Viswanathan

Steven J Chapin

Sayantan Mitra

Dylan L Daniel

Nicole G Lapuyade

Hsin Wang

Na Cai

Walter A Bogdanoff

Erwan Le Scolan

Hikmat Haizar Assi

Teddy Chen

Pehr B Harbury

David Lin

Robin Prince

Ian J Sas

Thomas Bouquin

Douglas Guptill

Amy Brideau-Andersen

Alexey Yevgenyevich Berezhnoy

Pehr Harbury

Brent R Larsen

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Activatable cytokine constructs and related compositions and methods

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Masked activatable interferon constructs

Provided herein are monoliths with attached recognition compounds which selectively bind ligands, methods of preparing such monoliths, arrays thereof and uses thereof. For example, monoliths provide herein can be used in columns and arrays thereof.

Monoliths with attached recognition compounds, arrays thereof and uses thereof

The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.

Immunosuppressive polypeptides and nucleic acids

The present invention provides evolved interferon-alpha polypeptides, and conjugates thereof, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Evolved interferon-alpha polypeptides

Growing community of inventors

San Francisco, CA, United States of America

Madan M Paidhungat